Cinclus Pharma Holding AB (FRA:J8P) Other Stockholders Equity: €2.20 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J8P Cinclus Pharma Holding AB FRA:J8P
6 GF Score
Price €1.10
! 3 Warning Signs
View Full Analysis

What is Cinclus Pharma Holding AB Other Stockholders Equity?

Cinclus Pharma Holding AB FRA:J8P +7.03% 6 Other Stockholders Equity is €2.20 Mil as of Mar. 2026. GuruFocus rates FRA:J8P with a GF Score™ of 6/100. The stock has 3 warning signs investors should review.

Cinclus Pharma Holding AB's Other Stockholders Equity for the quarter that ended in Mar. 2026 was €2.20 Mil.

Cinclus Pharma Holding AB's quarterly Other Stockholders Equity increased from Sep. 2025 (€2.15 Mil) to Dec. 2025 (€2.16 Mil) and increased from Dec. 2025 (€2.16 Mil) to Mar. 2026 (€2.20 Mil).

Cinclus Pharma Holding AB's annual Other Stockholders Equity increased from Dec. 2023 (€2.32 Mil) to Dec. 2024 (€2.49 Mil) but then declined from Dec. 2024 (€2.49 Mil) to Dec. 2025 (€2.16 Mil).

Cinclus Pharma Holding AB Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Cinclus Pharma Holding AB's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cinclus Pharma Holding AB Other Stockholders Equity Chart

Cinclus Pharma Holding AB Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
-0.47 1.53 2.32 2.49 2.16

Cinclus Pharma Holding AB Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.63 2.30 2.15 2.16 2.20
FRA:J8P
6GF Score
Cinclus Pharma Holding AB FRA:J8P
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cinclus Pharma Holding AB Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €2.20 Mil mean?
Cinclus Pharma Holding AB (FRA:J8P) has a Other Stockholders Equity of €2.20 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Cinclus Pharma Holding AB and its competitors.
Is Cinclus Pharma Holding AB's Other Stockholders Equity too high?
Cinclus Pharma Holding AB's current Other Stockholders Equity is €2.20 Mil. Overall, Cinclus Pharma Holding AB has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's Other Stockholders Equity compare to ZTS and UTHR?
Cinclus Pharma Holding AB's Other Stockholders Equity of €2.20 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Cinclus Pharma Holding AB and its competitors. Cinclus Pharma Holding AB's current Other Stockholders Equity is €2.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (FRA:J8P) has a current Other Stockholders Equity of €2.20 Mil. The current Other Stockholders Equity is €2.20 Mil. Cinclus Pharma Holding AB's overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Cinclus Pharma Holding AB (FRA:J8P), the current Other Stockholders Equity is €2.20 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cinclus Pharma Holding AB Business Description

Other Exchanges CINPHA:Sweden
Address Kungsbron 1, Stockholm, SWE, SE-111 22
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
6GF Score

Get the complete analysis for FRA:J8P

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.10
Price